Duchenne muscular dystrophy (DMD) is a neuromuscular disorder that results from mutations in the DMD gene. Gene therapies for DMD change genetic material in a person’s body to treat this condition.
Regenxbio’s gene therapy for Duchenne muscular dystrophy has smashed the primary endpoint of its pivotal trial, securing a ...
DMD gene therapy faces challenges in safety, efficacy, and long-term outcomes, despite FDA approval of delandistrogene moxeparvovec. Future strategies focus on novel AAV capsids, dual/triple vector ...
- PBGENE-DMD is a first-in-class in vivo gene editing approach for the majority of Duchenne Muscular Dystrophy patients impacted by dystrophin mutations in the most common ‘hot spot’ region between ...
Based on positive safety and efficacy data in the Phase 1/2 dose escalation phase of the all-in-one study, Genethon expects to launch pivotal trial in Europe in 2025 and in the US. The results showed ...
Duchenne muscular dystrophy (DMD) is caused by a mutation in the DMD gene that prevents dystrophin production, leading to progressive muscle weakness and early mobility challenges. The 2018 DMD ...
Duchenne muscular dystrophy (DMD) results from changes in the DMD gene. Children may inherit DMD gene changes from their parents or have spontaneous gene changes. The DMD gene tells the body how to ...
Clinical Trials Arena on MSN
REGENXBIO to push for accelerated approval of DMD gene therapy
REGENXBIO touted data from the Phase III portion of a study that showed higher benefit that Elevidys.
Duchenne muscular dystrophy (DMD) is a genetic condition that primarily affects people assigned male at birth. However, due to the condition’s X-linked inheritance pattern, only people assigned female ...
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results